Miscellaneous Ob/Gyn conditions:
Indications for HEMABATE:
For aborting pregnancy between the 13th and 20th weeks of gestation in the following conditions related to second trimester abortion: 1) failure of expulsion of the fetus during the course of treatment by another method; 2) premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3) requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4) inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. For the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management.
Give by deep IM inj. Abortion: 250mcg; subsequent doses of 250mcg should be given at 1.5–3.5 hour intervals depending on uterine response. Optional test dose (100mcg) may be given initially. Dose may be increased to 500mcg if uterine contractility is judged to be inadequate after several doses of 250mcg. Max total dose: 12mg; continuous administration for >2 days not recommended. Refractory postpartum uterine bleeding: initially 250mcg once, may give additional doses at intervals of 15–90 mins if necessary. Max total dose: 2mg (8 doses).
Acute pelvic inflammatory disease. Active cardiac, pulmonary, renal or hepatic disease.
Should only be used by trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities. Not indicated if fetus in utero has reached stage of viability. History of asthma, hypo- or hypertension, cardiovascular, renal, or hepatic disease, anemia, jaundice, diabetes, epilepsy. Compromised (scarred) uteri. Chorioamnionitis. Pregnancy (Cat.C).
Concomitant other oxytocic agents: not recommended.
Vomiting, diarrhea, nausea, flushing, chills, headache, pain, breast tenderness; transient pyrexia (see full labeling re: PGEs induced pyrexia vs. endometritis pyrexia), others.
Generic Drug Availability:
Ampules (1mL)—1, 10